当前位置: X-MOL 学术Mol. Genet. Genomic Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Oncogenic mutations within the β3-αC loop of EGFR/ERBB2/BRAF/MAP2K1 predict response to therapies.
Molecular Genetics & Genomic Medicine ( IF 2 ) Pub Date : 2020-08-05 , DOI: 10.1002/mgg3.1395
Biao Zhang 1 , Yongsheng Chen 2, 3 , Pingping Dai 2, 3 , Haoda Yu 4 , Jianhui Ma 2 , Chen Chen 2, 3 , Yan Zhang 2, 3 , Yanfang Guan 2, 3 , Rongrong Chen 2 , Tao Liu 2, 3 , Jiayin Wang 3 , Ling Yang 2 , Xin Yi 2 , Xuefeng Xia 2 , Haitao Ma 1
Affiliation  

β3‐αC loop is a highly conserved structural domain across oncogene families, which is a switch for kinase activity. There have been numerous researches on mutations within β3‐αC loop in EGFR, but relatively less in ERBB2, BRAF, and MAP2K1. In addition, previous studies mainly focus on β3‐αC deletion in EGFR, which is the most common type affecting kinase activity and driving lung cancer. Other mutation types are not well studied.

中文翻译:

EGFR / ERBB2 / BRAF / MAP2K1的β3-αC环内的致癌突变可预测对治疗的反应。

β3-αC环是癌基因家族中一个高度保守的结构域,是激酶活性的开关。已经有在β3-αC环中的突变大量研究EGFR,但相对较少ERBB2BRAFMAP2K1。此外,先前的研究主要集中在EGFR中的β3-αC缺失上,这是影响激酶活性并引发肺癌的最常见类型。其他突变类型还没有得到很好的研究。
更新日期:2020-10-12
down
wechat
bug